Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development
— S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation — The platform can address challenges associated with viscosity and achieve stable liquid formulation for over 200 mg/mL subcutaneous administration Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), launched today a new high-concentration formulation platform to support the […]